Evidence map›Paper›PMID 32123385›Full record

ArticleNature medicine2020

Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia.

Shorena Janelidze, Niklas Mattsson, Sebastian Palmqvist, Ruben Smith, Thomas G Beach, Geidy E Serrano, Xiyun Chai, Nicholas K Proctor, Udo Eichenlaub, Henrik Zetterberg and 5 more

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in Nature medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06246019 (The Clinical Impact of the Novel Alzheimer's Blood-based Biomarkers), which is not on this map. Cited by 751 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
751citing papers in PubMed, 7 pooled it
85.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06246019 unknown statusnot on this mapstarted 2024, after this paper: background citation

The Clinical Impact of the Novel Alzheimer's Blood-based Biomarkers: the PLASMAR Study

Typeobservational_patient_registrySponsorHospital del Mar Research Institute (IMIM)Ran2024 to 2025Enrolled200ConditionsAlzheimer Disease, Cognitive Impairment, Dementia, Neurodegenerative DiseasesArmsEarly adoption of blood-based biomarkers for Alzheimer's disease
3 · Its place in the literature

Who cites it

751 citing papers in PubMed, 7 syntheses or guidelines pooled it, 1,219 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. The relationship of soluble tau species with Alzheimer's disease amyloid plaque removal and tau pathology.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Trial
  13. Article
  14. Loneliness and Plasma Biomarkers of Neurodegeneration in Community-Dwelling Older Adults: Cross-Sectional and Longitudinal Analyses.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry · 2026
    Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

691 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 4 countries.

Shorena Janelidze *Clinical Memory Research Unit, Lund University, Lund, Sweden. shorena.janelidze@med.lu.se.ORCID http://orcid.org/0000-0003-2869-8378
Niklas Mattsson *Clinical Memory Research Unit, Lund University, Lund, Sweden.
Sebastian PalmqvistClinical Memory Research Unit, Lund University, Lund, Sweden.
Ruben SmithClinical Memory Research Unit, Lund University, Lund, Sweden.
Thomas G BeachBanner Sun Health Research Institute, Sun City, AZ, USA.
Geidy E SerranoBanner Sun Health Research Institute, Sun City, AZ, USA.
Xiyun ChaiEli Lilly and Company, Indianapolis, IN, USA.
Nicholas K ProctorEli Lilly and Company, Indianapolis, IN, USA.
Udo EichenlaubRoche Diagnostics GmbH, Penzberg, Germany.
Henrik ZetterbergDepartment of Psychiatry and Neurochemistry, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
Kaj BlennowDepartment of Psychiatry and Neurochemistry, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
Eric M ReimanBanner Alzheimer's Institute, Phoenix, AZ, USA.ORCID http://orcid.org/0000-0002-0705-3696
Erik StomrudClinical Memory Research Unit, Lund University, Lund, Sweden.
Jeffrey L DageEli Lilly and Company, Indianapolis, IN, USA.
Oskar HanssonClinical Memory Research Unit, Lund University, Lund, Sweden. Oskar.Hansson@med.lu.se.ORCID http://orcid.org/0000-0001-8467-7286
Lund University · SEEli Lilly (United States) · USBanner Sun Health Research Institute · USSahlgrenska University Hospital · SEBanner Alzheimer’s InstituteRoche Pharma AG (Germany) · DE

Funding

Research Education ComponentP30AG019610 · NIA · SUN HEALTH RESEARCH INSTITUTE · PI REIMAN, ERIC MICHAEL · 2001 to 2020
$32.5M
Research Education ComponentP30AG072980 · NIA · BANNER HEALTH · PI THOMAS G BEACH · 2021 to 2026
$24.9M
National Brain and Tissue Resource for Parkinson's Disease and Related DisordersU24NS072026 · NINDS · BANNER SUN HEALTH RESEARCH INSTITUTE · PI BEACH, THOMAS G · 2011 to 2015
$7.8M
NIA NIH HHS P30 AG019610NIA NIH HHS P30 AG072980NINDS NIH HHS U24 NS072026
6 · The paper itself

Abstract

Plasma phosphorylated tau181 (P-tau181) might be increased in Alzheimer's disease (AD), but its usefulness for differential diagnosis and prognosis is unclear. We studied plasma P-tau181 in three cohorts, with a total of 589 individuals, including cognitively unimpaired participants and patients with mild cognitive impairment (MCI), AD dementia and non-AD neurodegenerative diseases. Plasma P-tau181 was increased in preclinical AD and further increased at the MCI and dementia stages. It correlated with CSF P-tau181 and predicted positive Tau positron emission tomography (PET) scans (area under the curve (AUC) = 0.87-0.91 for different brain regions). Plasma P-tau181 differentiated AD dementia from non-AD neurodegenerative diseases with an accuracy similar to that of Tau PET and CSF P-tau181 (AUC = 0.94-0.98), and detected AD neuropathology in an autopsy-confirmed cohort. High plasma P-tau181 was associated with subsequent development of AD dementia in cognitively unimpaired and MCI subjects. In conclusion, plasma P-tau181 is a noninvasive diagnostic and prognostic biomarker of AD, which may be useful in clinical practice and trials.

Indexed as

Disease ProgressionAgedAlzheimer DiseaseAmyloid beta-PeptidesBiomarkersDementiaDiagnosis, DifferentialFemaleHumansLongitudinal StudiesMaleMiddle AgedMultivariate AnalysisNeuropathologyPhosphorylationProportional Hazards ModelsAmyloid beta-PeptidesBiomarkerstau Proteins

Identifiers

PMID32123385
OpenAlexW3009441391

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.